Clinical trials in Dordrecht – page 107

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Dordrecht at a glance

1 624

clinical trials

Research sites1

Quick filters

1 624 trials in Dordrecht

Open in trial search

Gastrooesophageal cancer+1

Not recruiting

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Retifanlimab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Sickle cell anaemia+1

Not recruiting

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Crizanlizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rilvegostomig
Sponsor:AstraZeneca AB

Contact Research Centre

Angina pectoris

Not recruiting

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Diltiazem Hydrochloride
Sponsor:Stichting Radboud universitair medisch centrum

Contact Research Centre

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Quizartinib Dihydrochloride
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Chronic graft versus host disease

Not recruiting

Study on the Safety and Effectiveness of Ibrutinib for Children and Young Adults with Chronic Graft Versus Host Disease

Registered drugNo placebo

Study on the Safety and Effectiveness of Ibrutinib for Children and Young Adults with Chronic Graft Versus Host Disease

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Ibrutinib
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Abbvie Deutschland GmbH & Co. KG

Contact Research Centre

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:PTC Therapeutics Inc.

Contact Research Centre

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

Blood Cancer Therapies
Leukemia Treatment
Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

Heart Disease Management
Blood Clot Prevention
Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

Thyroid Disease Management
Hormone Therapy
Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the Netherlands All countries